{
  "title": "EpiPen Prices, the Clinton Foundation, and Lead Exposure",
  "description": "Why did EpiPen's price skyrocket 400 percent over the past decade? Sarah and Matt dive into the complex world of American drug pricing to find out. Also on this episode: understanding why the Clinton Foundation gets so much scrutiny, and a white paper of the week that shows how problematic a small level of lead exposure can be.\n      \nLearn more about your ad choices. Visit podcastchoices.com/adchoices",
  "pubDate": "Wed, 31 Aug 2016 20:57:00 -0000",
  "itunes:title": "EpiPen Prices, the Clinton Foundation, and Lead Exposure",
  "itunes:episodeType": "full",
  "itunes:episode": 54,
  "itunes:author": "Vox",
  "itunes:image": "",
  "itunes:subtitle": "",
  "itunes:summary": "Why did EpiPen's price skyrocket 400 percent over the past decade? Sarah and Matt dive into the complex world of American drug pricing to find out. Also on this episode: understanding why the Clinton Foundation gets so much scrutiny, and a white paper of the week that shows how problematic a small level of lead exposure can be.\n      \nLearn more about your ad choices. Visit podcastchoices.com/adchoices",
  "content:encoded": "<p>\n        Why did EpiPen's price skyrocket 400 percent over the past decade? Sarah and Matt dive into the complex world of American drug pricing to find out. Also on this episode: understanding why the Clinton Foundation gets so much scrutiny, and a white paper of the week that shows how problematic a small level of lead exposure can be.\n      </p><p> </p><p>Learn more about your ad choices. Visit <a href=\"https://podcastchoices.com/adchoices\">podcastchoices.com/adchoices</a></p>",
  "itunes:duration": 3331,
  "guid": "986bdcae-4d1d-11e6-aeed-5317d1e4d480",
  "enclosure": ""
}